Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 6/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | XPO1 | O14980 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20673477 | 1.00 | LMNA (0.54) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL19403560 | 1.00 | LMNA (0.54) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL19385635 | 1.00 | LMNA (0.54) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL20673533 | 0.89 | MAPT (0.53) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL19403818 | 0.89 | AR (0.69) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL19403820 | 0.89 | AR (0.69) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL26327887 | 0.89 | AR (0.58) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL20673789 | 0.89 | AR (0.69) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL19403821 | 0.89 | AR (0.69) | LMNAMAPTMEN1ALDH1A1TSHR | |
| SCHEMBL19403819 | 0.89 | AR (0.69) | LMNAMAPTMEN1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017165822-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | LMNA 4118/4885MAPT 4386/4885MEN1 3409/4885 |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | LMNA 4166/4885MAPT 4364/4885MEN1 3639/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | LMNA 4159/4885MAPT 4362/4885MEN1 3572/4885 |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | LMNA 4159/4885MAPT 4362/4885MEN1 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.